U.S. Markets close in 4 hrs 35 mins

GlaxoSmithKline Stock Slumps on News of Tesaro Deal

Teresa Rivas

Glaxo investors aren’t enthused for the biopharma acquisition, which won’t add to the company’s bottom line for years.